IP Library Granted Patent US 9,328,157
Granted Patent B2
US 9,328,157 · App. 14/071,069 · Granted May 3, 2016

Inhibitors of type 2 vascular endothelial growth factor receptors

Inventors: Yan Chen (Lexington, MA); Elena Getmanova (Lexington, MA); Martin C. Wright (Boston, MA); Alan S. Harris (Andover, MA); Ai Ching Lim (Mercer Island, WA); Jochem Gokemeijer (Boston, MA); Lin Sun (West Roxbury, MA); Michael Wittekind (Bainbridge Island, WA)
Assignee: BRISTOL-MYERS SQUIBB COMPANY
C07K14/78C07H21/04C07K14/4703C07K14/52C07K16/2863C07K16/30A61K38/00A61K38/39A61K2039/505C07K2317/34C07K2317/73C07K2317/92C07K2318/20
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,328,157
App. No.
14/071,069
Granted
May 3, 2016
Kind
B2
Abstract

The present disclosure relates to novel vascular endothelial growth factor receptor (VEGFR)-binding polypeptides and methods for using these polypeptides to inhibit biological activities mediated by vascular endothelial growth factors (VEGFs). The present disclosure also provides various improvements relating to single domain binding polypeptides.

Claims (7)

1. A polypeptide comprising a modified fibronectin type III tenth ( 10 Fn3) domain, wherein the modified 10 Fn3 domain (i) comprises a modified amino acid sequence in one or more of the AB, BC, CD, DE, EF and FG loops relative to the wild-type 10 Fn3 domain set forth in SEQ ID NO: 5, (ii) comprises an amino acid sequence that is at least 60% identical to SEQ ID NO: 5, (iii) binds to a target molecule not bound by the wild-type 10 Fn3 domain, and (iv) comprises a C-terminal tail comprising the amino acid sequence EIDKPSQ (residues 88-94 of SEQ ID NO: 184) or EIDKPCQ (residues 88-94 of SEQ ID NO: 194).

2. An isolated nucleic acid encoding the polypeptide of claim 1 .

3. A polypeptide comprising a modified fibronectin type III tenth ( 10 Fn3) domain, wherein (i) amino acid residues 1 to 8 of the wild-type 10 Fn3 domain set forth in SEQ ID NO: 5 are deleted, (ii) the modified 10 Fn3 domain comprises a modified amino acid sequence in one or more of the AB, BC, CD, DE, EF and FG loops relative to the wild-type 10 Fn3 domain, (iii) the modified 10 Fn3 domain comprises an amino acid sequence that is at least 60% identical to SEQ ID NO: 5, (iv) the modified 10 Fn3 domain binds to a target molecule not bound by the wild-type 10 Fn3 domain, and (v) wherein binding of the polypeptide to the target molecule is increased relative to a polypeptide which is identical in amino acid sequence but which comprises the N-terminal amino acid sequence VSDVPRDL (residues 1-8 of SEQ ID NO: 5).

4. The polypeptide of claim 3 , wherein the polypeptide comprises a C-terminal tail comprising the amino acid sequence EIDKPSQ (residues 88-94 of SEQ ID NO: 184) or EIDKPCQ (residues 88-94 of SEQ ID NO: 194).

5. The polypeptide of claim 3 , wherein the N-terminal amino acid of the modified 10 Fn3 domain is glycine.

6. The polypeptide of claim 3 , wherein 1 to 7 amino acids are added to the C-terminus of the modified 10 Fn3 domain.

7. An isolated nucleic acid encoding the polypeptide of claim 3 .

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 23, 2015
From: CHEN, YAN; GETMANOVA, ELENA; WRIGHT, MARTIN C.; HARRIS, ALAN S.; LIM, AI CHING; GOKEMEIJER, JOCHEM; SUN, LIN; WITTEKIND, MICHAEL
To: BRISTOL-MYERS SQUIBB COMPANY
Reel/Frame 037121/0155 →
Continuity (6)
Continuation 13552398 · Jul 18, 2012
Continuation 12788240 · May 26, 2010
Continuation 11448171 · Jun 5, 2006
Continuation PCTUS2004040885 · Dec 6, 2004
Provisional Application 60527886 · Dec 5, 2003
Related Publication 20140179896A1 · Jun 26, 2014